… S Dolly … S Popat … Gronberg BH, Bremnes RM, Aasebo U, Brunsvig P, Flotten O, Amundsen
T, von Plessen C, Wang M, Sundstrom S (2008) A prospective phase II study: high-dose …

Background Patients with cancer are purported to have poor COVID-19 outcomes. However,
cancer is a heterogeneous group of diseases, encompassing a spectrum of tumour …

Non-small-cell lung cancer (NSCLC) remains a significant global health challenge and the
leading cause of cancer-related mortality. The traditional ‘one-size-fits-all’ treatment …

Importance Whether the severity and mortality of COVID-19 in patients with cancer have
improved in terms of disease management and capacity is yet to be defined. Objective To test …

Purpose: This phase I study assessed the maximum tolerated dose (MTD), dose-limiting
toxicities (DLT), safety, pharmacokinetics, pharmacodynamics, and clinical activity of the first-in-…

The last decade has witnessed rapid advances in the discovery and development of immune
checkpoint inhibitors in cancer medicine, particularly drugs targeting programmed cell …

Background The omicron (B.1.1.529) variant of SARS-CoV-2 is highly transmissible and
escapes vaccine-induced immunity. We aimed to describe outcomes due to COVID-19 during …

… at Guy’s and St Thomas’ Hospital and the 64 patients who tested positive at King’s College
… only entered if present in the patient’s medical record. Ethnicity information was collected …

Background Using an updated dataset with more patients and extended follow-up, we further
established cancer patient characteristics associated with COVID-19 death. Methods Data …

Purpose: This first-in-human phase I trial assessed the safety, tolerability, and preliminary
antitumor activity of apitolisib (GDC-0980), a dual inhibitor of class I PI3K, and mTOR kinases. …